EvoEndo is developing platforms for unsedated transnasal endoscopies. Its single-use endoscopy system received FDA 510(k) clearance in February 2022, according to an April 13 news release from the company.
The EvoEndo system is designed to allow hospitals to move endoscopy procedures from an ambulatory procedural suite to an office-based environment, saving sedation procedure rooms for more complex cases.
Capital for the AGA’s venture fund will be provided by venture capital platform Varia Ventures, the release said.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.